Canopy Growth

Poland Restrictions And Rising Costs Will Constrain Global Expansion

AnalystLowTarget

Not Invested

Community Contributor

Published

12 Aug 25

AnalystLowTarget's Fair Value

CA$0

n/a

04 Sep

CA$1.92

-66.4%

-5.9%

-66.4%

-5.9%

You can edit this narrative until Aug 12 10:21 PM. Then, changes will post as Updates.

Author's Valuation

CA$0n/a

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

CA$0

n/a

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.82%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

CA$3.31m

Earnings '28

0.00x

PE Ratio '28

CA$0

Market Cap '28

CA$0

Market Cap '28

526.95m

No. shares '28

CA$0

Share Price '28

CA$0 Share Price '28

Discounted to 2025 @ 5.97% p.a.

CA$0

Fair Value '25